Risk of perioperative bleeding related to highly selective cyclooxygenase-2 inhibitors: A systematic review and meta-analysis

Seminars in Arthritis and Rheumatism

Volumn 46, Issue 4, 2017, Pages 520-528

  Teerawattananon, Choochai ^a   Tantayakom, Pongchirat ^b   Suwanawiboon, Bundarika ^a   Katchamart, Wanruchada ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Mahidol University   (Thailand)

Author keywords

Highly selective COX 2 inhibitor; Non selective non steroidal anti inflammatory drug; Periooperative bleeding; Platelet function; Systematic review

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; FLURBIPROFEN; HEMOGLOBIN; IBUPROFEN; KETOPROFEN; KETOROLAC; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PARECOXIB; PLACEBO; ISOXAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; SULFONE;

ARTICLE; CLINICAL OUTCOME; DRUG USE; HIGH RISK PATIENT; HUMAN; LABORATORY TEST; META ANALYSIS; OPERATIVE BLOOD LOSS; OUTCOME ASSESSMENT; POSTOPERATIVE HEMORRHAGE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SINGLE DRUG DOSE; SURGICAL PATIENT; SYSTEMATIC REVIEW; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION ANALYZER; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

BLOOD LOSS, SURGICAL; CELECOXIB; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; ISOXAZOLES; POSTOPERATIVE HEMORRHAGE; PYRIDINES; RISK FACTORS; SULFONES;

EID: 84994143441     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2016.07.008     Document Type: Article

References (49)

1. [1] Cancer pain relief. Switzerland: World Health Organization Geneva; 1986.
2. [2] Wolfe, M.M., Lichtenstein, D.R., Singh, G., Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340 (1999), 1888–1899.
3. [3] Whelton, A., Hamilton, C.W., Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 31 (1991), 588–598.
4. [4] Knijff-Dutmer, E., Kalsbeek-Batenburg, E., Koerts, J., van de Laar, M., Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclooxygenase-2 selective inhibitors in patients with rheumatoid arthritis. Rheumatology 41 (2002), 458–461.
5. [5] Hernández-Dı́az, S., Garcı́a-Rodrı́guez, L.A., Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med 110 (2001), 20–27.
6. [6] Fu, J.Y., Masferrer, J.L., Seibert, K., Raz, A., Needleman, P., The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265 (1990), 16737–16740.
7. [7] Dubois, R.N., Abramson, S.B., Crofford, L., Gupta, R.A., Simon, L.S., A. Van De Putte, L.B., et al. Cyclooxygenase in biology and disease. FASEB J 12 (1998), 1063–1073.
8. [8] Coxib and traditional NSAID Trialistsʼ (CNT) Collaboration, Bhala, N., Emberson, J., Merhi, A., Abramson, S., Arber, N., et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382 (2013), 769–779.
9. [9] Schnitzer, T.J., Burmester, G.R., Mysler, E., Hochberg, M.C., Doherty, M., Ehrsam, E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 (2004), 665–674.
10. [10] Geerts, W.H., Bergqvist, D., Pineo, G.F., Heit, J.A., Samama, C.M., Lassen, M.R., et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (2008), 381S–453S.
11. [11] Higgins, J.P.T., Altman, D.G., Gøtzsche, P.C., Jüni, P., Moher, D., Oxman, A.D., et al. The Cochrane Collaborationʼs tool for assessing risk of bias in randomised trials. Br Med J, 2011, 343.
12. [12] Simon, L.S., Lanza, F.L., Lipsky, P.E., Hubbard, R.C., Talwalker, S., Schwartz, B.D., et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 41 (1998), 1591–1602.
13. [13] McAdam, B.F., Catella-Lawson, F., Mardini, I.A., Kapoor, S., Lawson, J.A., FitzGerald, G.A., Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 96 (1999), 272–277.
14. [14] Leese, P.T., Hubbard, R.C., Karim, A., Isakson, P.C., Yu, S.S., Geis, G.S., Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 40 (2000), 124–132.
15. [15] Noveck, R.J., Laurent, A., Kuss, M., Talwalker, S., Hubbard, R.C., Parecoxib sodium does not impair platelet function in healthy elderly and non-elderly individuals: two randomised, controlled trials. Clin Drug Invest 21 (2001), 465–476.
16. [16] Wilner, K.D., Rushing, M., Walden, C., Adler, R., Eskra, J., Noveck, R., et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J Clin Pharmacol 42 (2002), 1027–1030.
17. [17] Munsterhjelm, E., Niemi, T.T., Ylikorkala, O., Neuvonen, P.J., Rosenberg, P.H., Influence on platelet aggregation of i.v. parecoxib and acetaminophen in healthy volunteers. Br J Anaesth 97 (2006), 226–231.
18. [18] Graff, J., Skarke, C., Klinkhardt, U., Watzer, B., Harder, S., Seyberth, H., et al. Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers. J Thromb Haemost 5 (2007), 2376–2385.
19. [19] Gladding, P.A., Webster, M.W., Farrell, H.B., Zeng, I.S., Park, R., Ruijne, N., The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 101 (2008), 1060–1063.
20. [20] Schwartz, J.I., Dallob, A.L., Larson, P.J., Laterza, O.F., Miller, J., Royalty, J., et al. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. J Clin Pharmacol 48 (2008), 745–754.
21. [21] Lee, W., Suh, J.W., Yang, H.M., Kwon, D.A., Cho, H.J., Kang, H.J., et al. Celecoxib does not attenuate the antiplatelet effects of aspirin and clopidogrel in healthy volunteers. Korean Circ J 40 (2010), 321–327.
22. [22] Meek, I.L., Vonkeman, H.E., Kasemier, J., Movig, K.L.L., Van De Laar, M.A.F.J., Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol 69 (2013), 365–371.
23. [23] Khan, A.A., Brahim, J.S., Rowan, J.S., Dionne, R.A., In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model. Clin Pharmacol Ther 72 (2002), 44–49.
24. [24] Karamanlioglu, B., Arar, C., Alagol, A., Colak, A., Gemlik, I., Sut, N., Preoperative oral celecoxib versus preoperative oral rofecoxib for pain relief after thyroid surgery. Eur J Anaesthesiol 20 (2003), 490–495.
25. [25] Bajaj, P., Ballary, C.C., Dongre, N.A., Baliga, V.P., Desai, A.A., Comparison of the effects of parecoxib and diclofenac in preemptive analgesia: a prospective, randomized, assessor-blind, single-dose, parallel-group study in patients undergoing elective general surgery. Curr Ther Res Clin Exp 65 (2004), 383–397.
26. [26] Nikanne, E., Kokki, H., Salo, J., Linna, T.J., Celecoxib and ketoprofen for pain management during tonsillectomy: a placebo-controlled clinical trial. Otolaryngol Head Neck Surg 132 (2005), 287–294.
27. [27] Reuben, S.S., Ekman, E.F., The effect of cyclooxygenase-2 inhibition on analgesia and spinal fusion. J Bone Joint Surg Am 87 (2005), 536–542.
28. [28] Puura, A., Puolakka, P., Rorarius, M., Salmelin, R., Lindgren, L., Etoricoxib pre-medication for post-operative pain after laparoscopic cholecystectomy. Acta Anaesthesiol Scand 50 (2006), 688–693.
29. [29] Martinez, V., Belbachir, A., Jaber, A., Cherif, K., Jamal, A., Ozier, Y., et al. The influence of timing of administration on the analgesic efficacy of parecoxib in orthopedic surgery. Anesth Analg 104 (2007), 1521–1527.
30. [30] Meunier, A., Lisander, B., Good, L., Effects of celecoxib on blood loss, pain, and recovery of function after total knee replacement: a randomized placebo-controlled trial. Acta Orthop 78 (2007), 661–667.
31. [31] Huang, Y.M., Wang, C.M., Wang, C.T., Lin, W.P., Horng, L.C., Jiang, C.C., Perioperative celecoxib administration for pain management after total knee arthroplasty—a randomized, controlled study. BMC Musculoskelet Disord, 9, 2008, 77, 10.1186/1471-2474-9-77.
32. [32] Jirarattanaphochai, K., Thienthong, S., Sriraj, W., Jung, S., Pulnitiporn, A., Lertsinudom, S., et al. Effect of parecoxib on postoperative pain after lumbar spine surgery: a bicenter, randomized, double-blinded, placebo-controlled trial. Spine 33 (2008), 132–139.
33. [33] Siddiqui, A.K., Sadat-Ali, M., Al-Ghamdi, A.A., Mowafi, H.A., Ismail, S.A., Al-Dakheel, D.A., The effect of etoricoxib premedication on postoperative analgesia requirement in orthopedic and trauma patients. Saudi Med J 29 (2008), 966–970.
34. [34] Wattchow, D.A., De Fontgalland, D., Bampton, P.A., Leach, P.L., McLaughlin, K., Costa, M., Clinical trial: the impact of cyclooxygenase inhibitors on gastrointestinal recovery after major surgery—a randomized double blind controlled trial of celecoxib or diclofenac vs. placebo. Aliment Pharmacol Ther 30 (2009), 987–998.
35. [35] Gehling, M., Arndt, C., Eberhart, L.H.J., Koch, T., Kruger, T., Wulf, H., Postoperative analgesia with parecoxib, acetaminophen, and the combination of both: a randomized, double-blind, placebo-controlled trial in patients undergoing thyroid surgery. Br J Anaesth 104 (2010), 761–767.
36. [36] Ji, F.H., Jin, X., Yang, J.P., Zan, L.L., Analgesic effect of parecoxib and flurbiprofen axetil for patients undergoing laparoscopic cholecystectomy and their influences on platelet aggregation. Chin Med J (Engl) 123 (2010), 1607–1609.
37. [37] Gammaitoni, A., Viscusi, E., Hartrick, C., Frenkl, T., Peloso, P., Ko, A., et al. Perioperative use of etoricoxib reduces pain and opioid side-effects after total abdominal hysterectomy: a double-blind, randomized, placebo-controlled phase III study. Curr Med Res Opin 28 (2011), 1323–1335.
38. [38] Sandhu, T., Paiboonworachat, S., Ko-iam, W., Effects of preemptive analgesia in laparoscopic cholecystectomy: a double-blind randomized controlled trial. Surg Endosc 25 (2011), 23–27.
39. [39] Gong, L., Dong, J.Y., Li, Z.R., Effects of combined application of muscle relaxants and celecoxib administration after total knee arthroplasty (TKA) on early recovery: a randomized, double-blind, controlled study. J Arthroplasty 28 (2013), 1301–1305.
40. [40] Zende, A.M., Bhosale, R.R., Comparison of postoperative analgesic efficacy and safety of parecoxib and ketorolac in patients of inguinal hernia. Int J Basic Clin Pharmacol 2 (2013), 414–420.
41. [41] Dirkmann, D., Groeben, H., Farhan, H., Stahl, D.L., Eikermann, M., Effects of parecoxib on analgesia benefit and blood loss following open prostatectomy: a multicentre randomized trial. BMC Anesthesiol 15 (2015), 1–9.
42. [42] Claria, J., Kent, J.D., Lopez-Parra, M., Escolar, G., Ruiz-del-Arbol, L., Gines, P., et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology 41 (2005), 579–587.
43. [43] Dragani, A., Pascale, S., Recchiuti, A., Mattoscio, D., Lattanzio, S., Petrucci, G., et al. The contribution of cyclooxygenase-1 and 2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood 115 (2010), 1054–1061.
44. [44] Renda, G., Tacconelli, S., Capone, M.L., Sacchetta, D., Santarelli, F., Sciulli, M.G., et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther 80 (2006), 264–274.
45. [45] Scharbert, G., Gebhardt, K., Sow, Z., Duris, M., Deusch, E., Kozek-Langenecker, S., Point-of-care platelet function tests: detection of platelet inhibition induced by nonopioid analgesic drugs. Blood Coagul Fibrinolysis 18 (2007), 775–780.
46. [46] Hegazy, E.M., El-Hady, N.A., Abdallah, M.W., Comparative study of postoperative analgesic effects of parecoxib versus ketorolac and placebo in cervical disc surgery. Egypt J Anaesth 19 (2003), 179–182.
47. [47] Arafa, A.S., El-Kerdawy, H., Hafez, N., El-Agati, A., A comparative study of the efficacy and tolerability of parecoxib, tramadol, and parecoxib plus tramadol for postoperative pain management after oral surgery. Egypt J Anaesth 20 (2004), 283–290.
48. [48] El-Halafawy, Y.M., Abu-El-Kasem, O., Parecoxib for pain management after off-pump coronary artery bypass grafting. Egypt J Anaesth 20 (2004), 245–251.
49. [49] Florescu, S.C., Anastase, D.M., Munteanu, A.M., Stoica, I.C., Antonescu, D., Perioperative etoricoxib administration reduces postoperative opioid consumption without affecting transfusion requirements in total hip arthroplasty. Rom J Anaesth Int Care 20 (2013), 31–36.